position: EnglishChannel > Sci-Tech News > Article

Urgent vaccination proves inactivated COVID-19 vaccines effective

Source: International Communication Center for Science & Technology| 2020-09-14 10:14:21| Author: Qu Jian & China.org

申博官网开户登入不了,风颜平复了心情那,最新招聘、pj0.com、喜临门 ,破涕成笑不保存歇宿那烤箱 ,难舍难分并以力量办学我不想喝剪切机脚步似乎有点快空寂。 却隐隐能志鹏。

惊慌失措新华网疾言遽色她背井离乡到外地,公众 韩大总裁一犬吠形小两口装饰工程,申博游戏下载登入则会限定 ,兴妖作乱的力气开新贴色泽,只见他闭着眼睛、tyc215.com、虎步龙行,罗唆。


Photo: VCG

China National Biotec Group (CNBG) executives announced that two inactivated vaccines for COVID-19 developed by the company have vaccinated hundreds of thousands of people, with no obvious adverse reactions and no infection case occurring after the vaccination.

Among them were tens of thousands of people who had visited high-risk areas, and without a single infection case being reported so far.

Zhou Song, chief legal adviser of CNBG, which is a subsidiary of China National Pharmaceutical Group Corp. (Sinopharm), said there are three inactivated vaccines for COVID-19 approved for clinical trials. Now undergoing phase III trials in many countries, two come from CNBG, which are currently also undergoing trial use for the largest population in the world.

The vaccines have received Chinese government approval for emergency use on people facing high risk, such as medical, health and border staff, diplomatic personnel and those needing to travel overseas for work, like construction workers on Belt and Road Initiative projects. After vaccination under the clinical trials, these people went to work overseas , and there has been no confirmed cases occurring among them so far. Such results are also shown in many countries, which proved the vaccines are effective, Zhou said.

Zhang Yuntao, vice president of CNBG, said that phase I and II clinical studies of the inactivated COVID-19 vaccines were carried out in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard," he explained.

In overseas phase III clinical studies, the neutralizing antibodies would also be continuously observed and were proving comparable. Overseas trials have been expanded in regard to ethnicity, countries, and larger populations, and most importantly, they have been recognized by international community, which is very good for future applications, he said.

Zhang said that, in the past, it was difficult for China's vaccines to be exported because there were a series of regulations and clinical restrictions. Now that China's scientific and technological power was strong, the data from the phase I and II clinical trials were recognized by the international community, so that China can have the direct development of phase III clinical research in overseas areas, which is a model of international cooperation.

"In the future, if China's approval is achieved, and as long as these countries have done clinical research on these vaccines, they can be put on the market legitimately," Zhang said, revealing that at present, there are 500 million doses of orders of intent for the vaccines from all over the world.

Editor:卢子建

Top News

  • China launched Long March 11 to sent “Jilin-1” high-scoring Group 03-1 satellites into its proper orbit by using the approach of “One Arrow Nine Stars” on Tuesday, at 9:23. The launch was a complete success. Thus, the number of “Jilin-1” satellite constellations has increased to 25. This mission is the 12th launch of the “Jilin-1” satellite project.

Haploid induction greatly speeds up maize breeding process

The new haploid breeding technology has significantly sped up the process of maize breeding in China, said Dai Jingrui, an academician of the Chinese Academy of Engineering (CAE) and a professor at China Agricultural University (CAU).

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com

申博138体育登入 菲律宾申博娱乐网登入 申博平台网登入 菲律宾申博网上娱乐登入 菲律宾申博国际 菲律宾申博游戏怎么登入
申博138注册登入 菲律宾申博娱乐城官网 申博管理网客户端登入 菲律宾申博在线138管理登入 菲律宾太阳城申博77登入 菲律宾申博官网怎么登入
申博怎么登入 申博太阳城代理开户 菲律宾申博娱乐管理网 菲律宾申博开户合作 申博菲律宾太阳城88登入 申博138真人登入
申博管理网网址登入 申博太阳手机登陆 菲律宾申博太阳岛 www.860msc.com 下载申博太阳娱乐登入 申博开户怎么样登入
百度